Home | Welcome to Contract Pharma   
Last Updated Friday, May 24 2013
Print

Industry News

Related Searches:

Filter by:

April 22, 2008
Genzyme Corp. has plans to build a new R&D center in Beijing as part of its ongoing global expansion and commitment to establishing a long-term presence in China. The total cost for the project is estimated to be $90 million.    …   Read More »
April 18, 2008
Patheon has completed the sale of its York Mills facility in Toronto, Canada for $12.3 million. The agreement to sell the facility, announced in December 2007, is part of Patheon's global restructuring plan.     The company is curr…   Read More »
April 17, 2008
Eli Lilly and Co. announced plans to streamline a portion of its manufacturing operations in Indianapolis in an effort to align manufacturing capacity and engineering support services with the needs of the business. This streamlining affects sites th…   Read More »
April 17, 2008
GlaxoSmithKline and Regulus Therapeutics have entered into a worldwide strategic alliance to discover, develop and market novel microRNA-targeted therapeutics to treat inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease.…   Read More »
April 15, 2008
Roche announced plans to acquire Piramed Limited, a privately-owned UK company focusing on therapeutics targeting PI3-kinase (PI3-K). Roche will spend $160 million on the acquisition, along with a $15 million milestone payment, due upon commencement…   Read More »
April 14, 2008
Alcon plans to build a facility in Singapore that will manufacture pharmaceuticals to be distributed throughout most of Asia. The company plans to break ground in 2009, with the plant becoming fully functional in 2012. Alcon will employ more than 150…   Read More »
April 11, 2008
Laureate Pharma, Inc. has entered into a contract manufacturing agreement with Alopexx Pharmaceuticals to produce Alopexx's mAb F598 antibody under cGMP conditions. This antibody will be used in clinical trials and later for commercial production for…   Read More »
April 10, 2008
Takeda Pharmaceutical Co. Ltd. and Millennium Pharmaceuticals, Inc. have entered into a definitive agreement under which Takeda will acquire Millennium for approximately $8.8 billion in cash. Upon completion of the acquisition, Millennium will become…   Read More »
April 10, 2008
Patheon has opened its new early phase development facility in Milton Park in Oxfordshire, UK. The 13,500-sq.-ft development facility has newly constructed formulation labs and a fully equipped analytical lab. The facility will focus on the early pha…   Read More »
April 9, 2008
Pfizer has updated the U.S. product labeling for Exubera (insulin human [rDNA original]) Inhalation Powder to include a warning with safety information about lung cancer cases observed in patients who used the drug.     This update…   Read More »
April 9, 2008
GlaxoSmithKline has received a warning letter from the FDA related to reporting requirements for approved medicines. The letter follows a routine inspection of the company's 2007 reporting processes.     The inspection revealed omis…   Read More »
April 9, 2008
Analytical Bio-Chemistry (ABC) Laboratories, Inc. has made a strategic organizational change aimed at supporting the drug development efforts of specialty, virtual and other small drug development companies. The company’s new Pharmaceutical Pro…   Read More »
April 7, 2008
Nestlé S.A. and Novartis AG have reached an agreement under which Nestlé will sell 74 million of its shares of Alcon, Inc. to Novartis in a cash transaction valued at $11 billion. Novartis would initially own a minority stake in Alcon o…   Read More »
April 7, 2008
Jubilant Organosys Ltd. and Draxis Health, Inc. have entered into an agreement whereby Jubilant will acquire all outstanding common shares of Draxis for approximately $255 million.     Mr. Shyam S. Bhartia, chairman and managing dir…   Read More »
April 7, 2008
Keryx Biopharmaceuticals is restructuring in an effort to reduce its cash burn rate and re-focus its development efforts. The restructuring plan, which follows the negative outcome of the company's Phase III trial of Sulonex for the treatment of diab…   Read More »
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:

Follow Contract Pharma On